Remdesivir, an antiviral drug commonly administered to COVID-19 patients, led to 601 deaths among military service members.

Infowars - com

<p>A recent article titled 'Remdesivir Papers' Allege Controversial Drug Used to Treat Service Members Led to 601 Deaths' has sparked controversy over the use of remdesivir, an antiviral drug commonly administered to COVID-19 patients. The article claims that a military whistleblower released documents revealing 601 deaths of military service members and a high rate of serious adverse events in clinical trials involving remdesivir. The article also alleges that some clinical trials were improperly run and that there was a widespread lack of informed consent for trial participants.</p>
<p>The claim that remdesivir led to 601 deaths among military service members is not supported by reliable scientific evidence. While there are concerns about the drug's efficacy and safety, the data presented in the article is not sufficient to conclusively link remdesivir to the reported deaths.</p>
<p>The article cites a study published in The Lancet that raised concerns about the efficacy of remdesivir, noting that administration of remdesivir was stopped early in China 'because of adverse events in 18 (12%)' of patients 'versus four (5%) who stopped placebo early.' However, this study does not provide evidence that remdesivir caused the reported deaths.</p>
<p>The article also cites a study published in JAMA Network Open that found that 'remdesivir treatment was not associated with survival,' with more deaths and longer hospital stays among those patients who received remdesivir compared to those who did not receive the drug. However, this study also does not provide evidence that remdesivir caused the reported deaths.</p>
<p>The article alleges that the military began 'liberally' administering remdesivir to service members who were suspected of having COVID-19 — months before the U.S. Food and Drug Administration (FDA) approved the drug. However, the article does not provide evidence that the military's use of remdesivir was improper or that it caused the reported deaths.</p>
<p>The article also alleges that key details about the risks of remdesivir were concealed from service members, depriving them of being able to provide informed consent. However, the article does not provide evidence that the military's informed consent process was inadequate or that it caused the reported deaths.</p>
<p>In conclusion, the claim that remdesivir led to 601 deaths among military service members is not supported by reliable scientific evidence. While there are concerns about the drug's efficacy and safety, the data presented in the article is not sufficient to conclusively link remdesivir to the reported deaths. Further research is needed to determine the safety and efficacy of remdesivir in the treatment of COVID-19.</p>
<p>References:</p>
<ul>
  <li><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext">The Lancet Stud</a>y</li>
</ul>

Claim Review: Remdesivir Papers Allege Controversial Drug Used to Treat Service Members Led to 601 Deaths

<h2>Introduction</h2>
<p>Remdesivir, an antiviral drug, has been widely promoted as a treatment for COVID-19 patients. However, the effectiveness and safety of this drug have been subjects of debate. This article aims to review the claim that Remdesivir is an effective treatment for COVID-19 patients and to provide a thorough analysis based on scientific evidence.</p>
<h2>What is Remdesivir?</h2>
<p>Remdesivir is a broad-spectrum antiviral drug that inhibits RNA polymerase, disrupting the production of vital RNA. It was initially developed to treat Ebola but has been repurposed for COVID-19 treatment.</p>
<h2>Claim Analysis</h2>
<p>The claim that Remdesivir is an effective treatment for COVID-19 patients is based on its approval by regulatory bodies such as the FDA, EU, and UK's drug regulator. However, several studies have cast doubt on its efficacy and safety.</p>
<h2>Scientific Evidence</h2>
<p>The World Health Organization's Solidarity Trial found that Remdesivir does not reduce mortality or the time COVID-19 patients take to recover. A study published in <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext">The Lancet</a> also found no statistically significant benefit from the treatment.</p>
<p>Furthermore, a review of Remdesivir on <a href="https://www.drugs.com/comments/remdesivir/">drugs.com</a> showed that 47% of reviewers had a negative experience with the drug, compared to 19.38% who had a positive experience.</p>
<h2>Side Effects and Safety Concerns</h2>
<p>Remdesivir has been associated with several side effects, including fast, pounding heartbeats, trouble breathing, wheezing, shivering, itching, sweating, facial swelling, severe headache, and a feeling of being about to pass out. Subsequent side effects may include nausea and abnormal liver function tests.</p>
<p>The UK's National Institute for Health and Care Excellence (NICE) reports that Remdesivir interacts with twelve other drugs, including chloroquine, hydroxychloroquine, and phenytoin. Doctors prescribing Remdesivir should be aware of these interactions to avoid potential harm to patients.</p>
<h2>Conclusion</h2>
<p>Based on the available scientific evidence, the claim that Remdesivir is an effective treatment for COVID-19 patients is not supported. The drug has shown minimal efficacy in clinical trials and is associated with significant side effects. It is crucial for healthcare providers to consider the risks and benefits carefully before prescribing Remdesivir to COVID-19 patients.</p>

Claim Review: Remdesivir as an Effective Treatment for COVID-19

<p>The claim that the UK government used Midazolam to prematurely end the lives of thousands of elderly people and falsely reported them as COVID-19 deaths has been circulating widely. This claim is based on several pieces of information, including the purchase of a large quantity of Midazolam, the use of Midazolam in care homes, and the correlation between Midazolam prescriptions and COVID-19 deaths.</p>
<p>Midazolam is a sedative drug commonly used in palliative care and for sedation before medical procedures. It is also associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. The claim suggests that the UK government purchased a two-year supply of Midazolam in March 2020 and that this drug was used to prematurely end the lives of elderly people in care homes, with their deaths being falsely reported as COVID-19 deaths.</p>
<p>However, there are several issues with this claim. Firstly, while it is true that the UK government purchased a large quantity of Midazolam in March 2020, this was done as part of national efforts to respond to the coronavirus outbreak and to reduce the likelihood of future shortages. The purchase of Midazolam was not unique to the UK, and many other countries also increased their stocks of sedatives and other drugs in response to the pandemic.</p>
<p>Secondly, while there was an increase in the number of prescriptions for Midazolam in April 2020, this does not necessarily mean that the drug was used to prematurely end the lives of elderly people. Midazolam is a commonly used drug in palliative care, and the increase in prescriptions may have been due to the increase in the number of people requiring end-of-life care during the pandemic.</p>
<p>Thirdly, the claim that the deaths of elderly people were falsely reported as COVID-19 deaths is not supported by any concrete evidence. While it is true that there were a large number of excess deaths in care homes during the pandemic, this does not necessarily mean that these deaths were caused by Midazolam or that they were falsely reported as COVID-19 deaths.</p>
<p>In conclusion, while there are some concerning correlations between the use of Midazolam and COVID-19 deaths, there is no concrete evidence to support the claim that the UK government used Midazolam to prematurely end the lives of thousands of elderly people and falsely reported them as COVID-19 deaths. This claim is largely unfounded and should be treated with caution.</p>

Claim Review: Midazolam and COVID-19 Deaths in the UK

<p>The claim that hospitals willingly subjected patients to deadly protocols during the COVID-19 pandemic to generate financial incentives from the government has been circulating widely. This claim is based on testimonials from nurses and the analysis of author Ken McCarthy, who investigated the treatment protocols implemented during the height of the pandemic.</p><p>McCarthy's book, 'What the Nurses Saw,' alleges that hospitals followed dangerous protocols from the National Institutes of Health (NIH), which were financially incentivized. One of the key issues highlighted is the use of the drug remdesivir, which was halted in Africa due to organ failure. Other factors contributing to high mortality rates included the denial of anti-inflammatory medications, the use of BiPAP masks, and the excessive use of ventilators.</p><p>However, the claim that hospitals were solely motivated by financial incentives is not supported by comprehensive evidence. A study analyzed more than 4,200 hospitals and found that over half did not experience financial distress due to COVID-19, even without government relief funds. Moreover, average operating margins increased from 2.8% before the pandemic to 6.5% from 2020 to 2021, indicating that many hospitals were financially stable or even profitable during this period.</p><p>It is important to note that the complexity of treating a novel virus like COVID-19 led to varied and sometimes ineffective treatment protocols. The use of remdesivir, for example, was based on initial studies suggesting its potential efficacy, but subsequent research has shown mixed results. The denial of anti-inflammatory medications and the use of ventilators were also part of evolving treatment guidelines that were not universally effective.</p><p>Furthermore, the claim that hospitals were financially incentivized to keep patients on ventilators for extended periods is not substantiated by reliable scientific sources. The use of ventilators was based on medical necessity and the severity of the patient's condition, rather than financial incentives.</p><p>In conclusion, while there may have been instances of suboptimal treatment protocols and financial incentives, the claim that hospitals willingly subjected patients to deadly protocols for financial gain is largely unfounded. The treatment of COVID-19 patients was complex and evolved over time, reflecting the challenges of managing a novel virus.</p>

Claim Review: Hospitals Subjected Patients to Deadly Protocols for Financial Gain

If you want to replace an existing title on a portal and you want the replaced title to be visible to you and your followers.

Move the mouse over the title and make a right click.

Select Remedia -> Alternate Title from the menu

In the pop-up window, enter a new title that you like.

The blue icon copies the existing title into the input field, so you don't have to type everything...

By pressing Submit, the title will be replaced, which will be visible to you and others who visit the pages.

(There is a possibility that you will have to reload the page for the changes to be visible)

You can contact one of the fact-checking organizations.

Claim rated as -> Choose from false to true

Add claimer -> Opens a pop-up window that allows you to search for existing people already registered in the system or to create a new profile of that person.

Claimed At -> Enter the link to the page where the claim was found. You can add more places and link more claim authors

Short description -> short content that is seen when sharing articles on social networks

Field for entering the content of the article.

After the article is published, it will be visible on the Remedia social network and to everyone who has the Remedia Chrome extension installed

And you can engage in debunking yourself.

CAUTION! Abusing the platform is not allowed, entering unverified, misleading or untrue content will result in the deletion of the entire account with all content

Canonical -> If you enter content that already exists somewhere (your property), you can enter a link and Remedia will try to enter the content in the provided fields.

Featured image -> Image that is displayed when you share an article on other social networks.

Write your title -> Enter the title of the article

The claim being reviewed -> Enter the claim here, but BEWARE! An assertion is not the entire statement someone has made, but something concise and unambiguous. Check the claim entry multiple times as each change will create a new claim in the system.

Claim made on -> date when someone published the claim.

After installing the Chrome extension, you can log in and use advanced functionalities. One of them is 'Dislike'.

By right-clicking on an article, the options provided by the Remedia extension are opened, by selecting Dislike, the article will become more transparent and less visible.

Your action will be visible to you and all people who follow you!

Alternate Title

1. Log in to the Remedia social network with a Google or Facebook account (link above right).

2. Install the Chrome extension (if you didn't)

4. Enter the email you used to open your Google or Facebook account. Submit.

5. After the input field appears, rewrite the code. Accept.

That's it! Now you can use the advanced functions of the Remedia Chrome extension.

Alternate Titles

Remedia's work so far:

Remedia, the best thing that happened to media!

On the Feed page, you can enter Status, Opinion and Claim Review

It is enough to enter the title, short description and content.

Below the fields for entering content, you will find fields for entering links. By entering page links in these fields, you 'show' the Chrome extension on which pages to display your content

Press Publish to publish your opinion. (It may be necessary to wait a moment while all links are generated)

Claim: "Remdesivir, an antiviral drug commonly administered to COVID-19 patients, led to 601 deaths among military service members." is Mostly False

Has beed claimed by:

Articles reviewing this claim:

Content you might like: